Knowledge Library

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor.  This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Immunology Oncology Tumor Models

VIEW

Expanded Applications of PDX Models

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Oncology Tumor Models

VIEW

One Stop Target-to-Hit Platform: STATs

STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation.  STATs are known to play a role in the pathogenesis of many different diseases (including cancer) and the development of drugs directly or indirectly targeting STAT signaling has become a major focus for discovery teams.  WuXi AppTec offers a comprehensive platform of biophysical …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Biophysical Assays Immunology Oncology Structural Biology

VIEW

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >

Resource Type: Article Blog
Resource Topic: Antibodies Autoimmune and Inflammatory Diseases Cell-based Assays in vivo Pharmacology Oligonucleotides Oncology

VIEW

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Cell-based Assays Oligonucleotides Oncology Tumor Models

VIEW

Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant non-small cell lung cancer. However, despite Enhertu’s clinical benefits, most patients inevitably experience disease progression and mortality. Understanding drug resistance mechanisms can aid in developing new treatment strategies for drug-resistant clinical patients. In this study, …Read More >

Resource Type: Latest Science Poster
Resource Topic: Cell-based Assays Oncology

VIEW

Covalent Fragment-based Drug Discovery: BTK Inhibitors

At the Covalent Drug Discovery 2023 Summit, we presented a case study on Bruton’s tyrosine kinase (BTK) and demonstrated how biochemical, biophysical, and structural biology methods were used to confirm hits, characterize binding kinetics, and evaluate the mode of interaction of covalent BTK inhibitors. Our hit-to-lead workflow showcases the importance of bioanalytical methods, orthogonal assays, …Read More >

Resource Type: Latest Science Poster
Resource Topic: Biochemical Assays Biophysical Assays Fragment-Based Drug Discovery Hit Finding Hit-to-Lead Structural Biology

VIEW

One Stop Target-to-Hit Platform: Helicases

RecQ helicases (BLM, WRN, RECQL, RECQL4, and RECQL5) are an important family of surveillance proteins that play critical roles in genome maintenance and stability. Inherited mutations in these helicases are linked to distinct human disease syndromes, as well as cancer. To support the discovery of potent and selective RecQ helicase inhibitors, WuXi AppTec offers a …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Biophysical Assays Oncology Rare Diseases Structural Biology

VIEW

One Stop Target-to-Hit Platform: CDKs and CDK-Cyclin Complexes

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells, making these molecules important targets for cancer treatment. To support the discovery of novel CDK inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and lead optimization …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Biophysical Assays Hit-to-Lead Lead Optimization Oncology Structural Biology

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!